OncoDaily’s Post

📢$80 Billion for Cancer Drugs, But LMICs Are Left Behind: Time to Rethink Research for Global Equity 📢 Over $80 billion is spent annually on cancer drug development, yet many innovations fail to reach low- and middle-income countries (LMICs), which bear 70% of the global cancer burden. Conducting cancer #clinicaltrials in LMICs is crucial for creating effective and equitable care. By running trials in LMICs, we can ensure the safety, efficacy and effectiveness of new therapies are tested on diverse populations, making them suitable for everyone, not just those in wealthier nations. This approach not only provides patients in these regions with early access to new therapies but also helps boost local clinical research capacity as an important driver for quality improvement of service delivery. At City Cancer Challenge, we support cities in addressing local service readiness to ensure the most essential service delivery infrastructure is in place to deliver appropriate care and enable local systems to fully attain the best possible outcomes from oncology medicines. Building clinical research capacity in LMICs can be an important driver of such readiness as it helps to upgrade essential services, strengthen quality improvement programmes and train (and retain) professionals committed to excellence. Thank you Darryl Sleep, MD, Amgen, Bob Li, Memorial Sloan Kettering Cancer Center, Cure4Cancer for cohosting this session with C/Can and Foreign Policy at #UNGA79 to raise awareness of this critical subject and Dr. Nwamaka Lasebikan, Nigerian Institute for Cancer Research and Treatment (NICRAT), for sharing your perspective from, C/Can city Abuja, Nigeria. Without building the system’s capacity, innovation will continue to bypass those who need it most. It’s time to rethink #cancerresearch and focus on closing the care gap. 🌍💪 https://lnkd.in/eYnGET6M (Foreign Policy @UNGA79 video) PS: Thank you Diogo de Sousa Neves for your support with this post. #wordsmatters #GlobalHealth #HealthEquity #Oncology

#PancreaticCancer poses a significant challenge to public health in 🇪🇺! Our Position Paper, co-developed with Pancreatic Cancer Europe, Cancer Patients Europe - CPE, epc european pancreatic club, and UEG - United European Gastroenterology, delves into the facts surrounding pancreatic cancer, outlining the current challenges and proposing actionable solutions in the next five years. Read the full paper ➡ https://lnkd.in/enhN8cSk #PancreaticCancer #EUElections #EUElection2024 #EU4Health #HealthUnion #EUCancerPlan #DigestiveCancers EU Health and Food Safety EU Science, Research and Innovation European Health and Digital Executive Agency (HaDEA) European Parliament European Commission EU Health Coalition WHO Regional Office for Europe IARC - International Agency for Research on Cancer / World Health Organization

Things noone tells you about cancer- You need Maths! Not just any mathematics, the weaseliest of maths STATISTICS! In this episode Prof Krishan Bhaskeran helps us out...... @shinecancersupport #shinecancersupport #cancerandmaths

As we mark Breast Cancer Awareness Month 🎀, I’m reflecting on the past research I conducted as an MPH student for my graduate thesis: 𝘼𝙣𝙖𝙡𝙮𝙯𝙞𝙣𝙜 𝙩𝙝𝙚 𝙄𝙢𝙥𝙖𝙘𝙩 𝙤𝙛 𝘼𝙞𝙧 𝙋𝙤𝙡𝙡𝙪𝙩𝙞𝙤𝙣 𝙤𝙣 𝘽𝙧𝙚𝙖𝙨𝙩 𝘾𝙖𝙣𝙘𝙚𝙧 𝙈𝙤𝙧𝙩𝙖𝙡𝙞𝙩𝙮 𝙞𝙣 𝘾𝙖𝙡𝙞𝙛𝙤𝙧𝙣𝙞𝙖. My thesis examined the connection between air quality—specifically, particulate matter 2.5 (PM 2.5)—and breast cancer mortality across California, right down to the zip code level. My findings revealed something powerful: where you live, and the air you breathe can directly impact your health outcomes. 📊 𝗪𝗵𝘆 𝗧𝗵𝗶𝘀 𝗠𝗮𝘁𝘁𝗲𝗿𝘀: Exposure to PM 2.5 has been linked to numerous health conditions, but its ties to breast cancer mortality bring up critical conversations about prevention and protection. Environmental health is community health, and it’s time we shine a light on these hidden connections to create healthier futures. 👩🏽⚕️ 𝗟𝗲𝘃𝗲𝗿𝗮𝗴𝗶𝗻𝗴 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗳𝗼𝗿 𝗨𝗿𝗴𝗲𝗻𝘁 𝗔𝗰𝘁𝗶𝗼𝗻: With my background in public health and data analysis, I’m passionate about using these insights to inform policy and community interventions. Breast cancer affects so many lives, and I aim to raise awareness of both prevention and the role of environmental factors in health disparities. 💬 𝗟𝗲𝘁’𝘀 𝗧𝗮𝗹𝗸 𝗦𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀: How do you see air quality influencing health where you are? Let’s discuss how we can integrate environmental health data to make a real difference in public health outcomes. Feel free to share your thoughts below or connect with me—together, we can amplify the urgency of this issue! Jamin Brazil

Leaving #ASCO2024 with excitement after great discussions with KOLs, friends, and diving into the #CLDN presentations that ignited my interest: - #CLDN18.2 #ADC - #AZD0901 (MMAE): Reported a remarkable 48% ORR in #GC. - #CLDN18.2 #bispecific - #IBI389 (CLDN18.2xCD3): Showcased an impressive ORR of 38.9% (with CLDN18.2 expression exceeding 40%) in #PDAC. - #CLDN18.2 #CAR T - #CT041-CG4006 phase 1 trial: Achieved a notable ORR of 38.8% in #GC. Anticipating further “breakthroughs” with #CLDN1 ❤️, #CLDN4, #CLDN6 at upcoming oncology conferences. Encouraged by the #CLDN potential to revolutionize disease management while advancing our understanding of this biology and targeting. See you #ESMO24.

Over the last decade, we at Philips Foundation have been dedicated to creating meaningful change in healthcare access, both globally and locally 🌍 In the Netherlands, we’ve collaborated with our partners to tackle pressing healthcare challenges and develop sustainable solutions. Together with Stichting Eindhoven Hartveilig, we are established a 6-minute cardiac arrest zone in Eindhoven to ensure faster emergency response and save lives. Our partnership with the Prinses Máxima Centrum voor kinderoncologie is helping with treatments for children with cancer, while Stichting GelijkGezond is helping us address healthcare inequities to reach underserved communities.   These efforts are focused on reducing waiting times, cutting costs, and improving outcomes in cardiac and cancer care, advancing our mission of making quality healthcare accessible to all. As we celebrate a decade of impact, Philips Foundation remains committed to building healthier futures through innovation and collaboration 💙 👉 Learn more about Philips Foundation’s work and impact: https://lnkd.in/daVZ3pVZ

Exciting Breakthrough in Cancer Treatment! Thrilled to share groundbreaking news from the National Cancer Institute (NCI) about a new treatment regimen showing promising results in aggressive B-cell lymphoma. In a recent clinical trial led by NCI researchers, a combination therapy called ViPOR has achieved significant remissions in patients with diffuse large B-cell lymphoma (DLBCL), a challenging type of cancer that often becomes resistant to standard treatments. ViPOR, a novel blend of five targeted drugs—venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide—targets multiple molecular pathways crucial for DLBCL survival. This approach has led to remarkable outcomes, with tumors shrinking in over half of the patients and complete remissions observed in nearly 40% of cases. Published in the New England Journal of Medicine, these findings underscore the importance of innovative, multi-targeted approaches in oncology. The regimen's ability to synergistically inhibit various survival pathways of DLBCL marks a significant advancement in personalized cancer treatment. The ViPOR regimen underwent a rigorous phase 1b/2 clinical trial involving 50 patients with relapsed or treatment-resistant DLBCL. The results demonstrated substantial efficacy, particularly in patients with non-GCB DLBCL and double-hit GCB DLBCL subtypes, highlighting its potential as a new therapeutic option for challenging cases. Moving forward, ongoing phase 2 studies aim to validate and expand the application of ViPOR across different subtypes of DLBCL and other resistant lymphomas. This collaborative effort continues to drive progress in cancer care, offering hope for extended survival and potential cures. For more details on this transformative study, please visit the link below: https://lnkd.in/eNwaBdq9 At MAE Group, we're bringing even more hope to cancer patients with Project Hope, our innovative thermobrachytherapy oncology medical device. This groundbreaking platform combines brachytherapy's localized radiation with hyperthermia to enhance cancer treatment. Project Hope offers hope to patients and families facing glioblastoma. Stay tuned for more updates! To learn more about Project Hope, visit our website: https://lnkd.in/eSSBmXBv #CancerResearch #MedicalInnovation #ClinicalTrials #Oncology #HealthcareInnovation

LCRF's fall e-newsletter is here, with updates about research, education, events, and more. Check your inbox, or read it at LCRF.org/enews. #LungCancer #LungCancerResearch

The recent EURACAN Board meeting brought together our European experts in the field of rare adult solid cancers in the presence of Urszula Demkow, Undersecretary of State, Polish Ministry of Health, Department of Rare Diseases and Beata Jagielska, Director of Maria Sklodowska-Curie National Research Institute of Oncology We gathered in #Warsaw to discuss our achievements and future operations for the next few years. 📅 Many thanks to all the participants for this fruitful meeting! #RareCancers #EuropeanCollaboration #EURACAN #Europeanunion European Health and Digital Executive Agency (HaDEA) European Commission